

Preliminary figures for fiscal 2010

€ in millions Unaudited figures	2010	2009	Growth in %	Growth in %, const. currencies
Sales revenue	432.9	401.2	7.9%	5.0%
• Europe ¹⁾	226.3	233.4	-3.1%	-3.5%
• North America ¹⁾	114.3	97.1	17.7%	12.1%
• Asia Pacific ¹⁾	74.6	55.2	35.0%	25.4%
• Other Markets ¹⁾	17.8	15.5	14.7%	14.7%
EBITA ²⁾	70.0	60.3		
EBITA margin ²⁾	16.2%	15.0%		
Net profit ^{2) 3)}	45.2	34.7		
Earnings per share in € ^{2) 3)}	2.81	2.04		

¹⁾ According to customers' location ²⁾ Underlying ³⁾ Excluding amortization

The Sartorius Stedim Biotech Group uses earnings before interest, taxes and amortization (EBITA) as the key figure for measuring performance and profitability of the Group. Amortization refers only to any potential amortization of goodwill and of the intangible assets measured within the scope of purchase price allocation according to IFRS 3 "Business Combinations." The key indicator "underlying EBITA" corresponds to the EBITA adjusted for non-operating items.

Strong overall development driven by dynamic growth in Asia and the U.S.

In 2010, Sartorius Stedim Biotech (SSB), a leading supplier for the biopharmaceutical industries, achieved a considerable increase in order intake and sales revenue. Single-use products, again with strong growth rates, contributed substantially to these results. Business with large-scale bioreactors and other biotechnological production systems also added positive momentum. While business in Asia and the U.S. expanded highly dynamically, it slightly declined in Europe. This was partly due to a base effect: The comparative year-earlier figures were significantly influenced by extraordinary business with producers of the H1N1 vaccine.

Profitability further increased

Sartorius Stedim Biotech further increased its strong profitability. Underlying earnings improved by 16.1% from 60.3 million euros to 70.0 million euros. The respective margin rose from 15.0% to 16.2%. Positive economies of scale especially contributed to this rise. In addition, favorable exchange rates had a positive impact of approximately half of a percentage point. Extraordinary expenses accounted for 3.0 million euros. Underlying earnings per share are at 2.81 euros, up from 2.04 euros in 2009.

Strong operating cash flow and financial position

In the reporting year, SSB generated a strong operating cash flow of 72.8 million euros. Due to the complete execution of the company's share buyback program with a volume of 61.3 million euros in total, net debt was up from 87.6 million euros to 102.8 million euros. However, reflected by an equity ratio of 55.6%, a gearing ratio of 0.3 and a net-debt-to-underlying-EBITDA ratio of 1.2, the financial position of the Sartorius Stedim Biotech Group remained very strong.

Sartorius Stedim Biotech S.A.
 Z.I. Les Paluds
 Avenue de Jouques
 B.P. 1051
 13781 Aubagne - France
www.sartorius-stedim.com

Press Contact:
 Petra Kirchhoff
 Phone +49 (0)551.308.1686

Goettingen, February 9, 2011

Positive outlook for 2011

Positive business development is expected to continue in the current year as well. For 2011, SSB projects sales revenue to grow between 6% and 8% in constant currencies. Along with growth in sales, profitability is forecasted to further increase. Without currency effects considered, the underlying EBITA margin is targeted to rise to approximately 17%. Furthermore, management anticipates a significantly positive operating cash flow.

The figures given above are subject to a final audit by statutory auditors.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference Call and Webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Wednesday, February 9, 2011, at 4:00 p.m. Central European Time (CET), in a webcast teleconference. You may dial into the teleconference starting at 3:45 CET at the following numbers:

Germany: +49 (0)69 5007 1305

France: +33 (0)1 70 99 42 98

UK: +44 (0)20 7806 1950

USA: +1 718 354 1385

The dial-in code is: 9225134;

to view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions". Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs nearly 2,600 people, and in 2010 earned sales revenue of 432.9 million euros according to preliminary figures.

Contact: Petra Kirchhoff, Vice President of Group Corporate Communications

Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany

Phone: +49 (0)551.308.1686; fax: +49 (0)551.308.3410

E-mail: petra.kirchhoff@sartorius.com; <http://www.sartorius-stedim.com>